Apricus Biosciences, Inc. is in the pharmaceutical industry primarily focusing on research and development using its drug delivery technology called NexACT. The Company is actively engaged in acquiring companies and in-licensing drugs that will complement its product portfolio.The Company's pipeline of approved and late stage NexACT based product candidates includes Vitaros, which is approved in Canada for the treatment of erectile dysfunction, Femprox for female sexual arousal disorder, MycoVa for onychomycosis excluding tinea pedis (nail fungal infection), RayVa for Raynaud�s Syndrome and PrevOnco for liver cancer. The Company's pipeline of late stage preclinical products includes Nupen for post-chemotherapy recovery of Neutrophil. In June, 2011, the Company sold Bio-Quant, Inc. (Bio-Quant). On December 29, 2011, the Company acquired Topotarget USA, Inc. In April 2013, the Company announced the sale of Totect (dexrazoxane HCl), and NitroMist (nitroglycerin sublingual aerosol).